Upon FDA approval, an effective launch strategy includes sending clinical and economic information to payers to aid in the development of coverage decisions. DKP's team of experienced consultants will draft a launch notification letter and outline the specific supporting information that should accompany the notification.
To ensure that a breadth of payers receives information on a new product or indication, DKP maintains a current database of target payers for mailing and emailing, including:
The DKP team will follow-up with a sampling of payers within each target population and determine if additional information is required.